Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) EBITDA: 2019-2024

Historic EBITDA for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to -$51.9 million.

  • GeneDx Holdings' EBITDA rose 5.20% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 102.62%. This contributed to the annual value of -$51.9 million for FY2024, which is 70.41% up from last year.
  • According to the latest figures from FY2024, GeneDx Holdings' EBITDA is -$51.9 million, which was up 70.41% from -$175.3 million recorded in FY2023.
  • GeneDx Holdings' EBITDA's 5-year high stood at -$51.9 million during FY2024, with a 5-year trough of -$549.0 million in FY2022.
  • In the last 3 years, GeneDx Holdings' EBITDA had a median value of -$175.3 million in 2023 and averaged -$258.7 million.
  • As far as peak fluctuations go, GeneDx Holdings' EBITDA slumped by 712.48% in 2020, and later spiked by 70.41% in 2024.
  • Over the past 5 years, GeneDx Holdings' EBITDA (Yearly) stood at -$241.3 million in 2020, then fell by 1.68% to -$245.4 million in 2021, then crashed by 123.72% to -$549.0 million in 2022, then skyrocketed by 68.06% to -$175.3 million in 2023, then spiked by 70.41% to -$51.9 million in 2024.